摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H-pyrimido[5',4':4,5]pyrrolo[1,2-a]azepin-4,8-diamine | 1451370-39-0

中文名称
——
中文别名
——
英文名称
(S)-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H-pyrimido[5',4':4,5]pyrrolo[1,2-a]azepin-4,8-diamine
英文别名
(12S)-8-quinolin-3-yl-1,3,5-triazatricyclo[7.5.0.02,7]tetradeca-2,4,6,8-tetraene-6,12-diamine
(S)-5-(quinolin-3-yl)-7,8,9,10-tetrahydro-6H-pyrimido[5',4':4,5]pyrrolo[1,2-a]azepin-4,8-diamine化学式
CAS
1451370-39-0
化学式
C20H20N6
mdl
——
分子量
344.419
InChiKey
IQUZNEIKIKAKGH-AWEZNQCLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    26
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    95.6
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:US08889666B2
    公开(公告)日:2014-11-18
    The present invention provides a new compound that has an inhibitory action against EGFR and that has cell growth inhibitory effects. The present invention further provides a pharmaceutical preparation useful for preventing and/or treating cancer, based on the EGFR inhibitory effect of the compound. A compound represented by the following Formula (I) or a salt thereof.
    本发明提供了一种新的化合物,具有抑制EGFR的作用,并具有细胞生长抑制作用。本发明还提供了一种基于该化合物的EGFR抑制作用,用于预防和/或治疗癌症的药物制剂。化合物的结构式如下(I),或其盐。
  • METHOD FOR PRODUCNG TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD
    申请人:TAIHO PHARMACEUTICAL CO., LTD.
    公开号:US20160115172A1
    公开(公告)日:2016-04-28
    An object of the present invention is to provide a method for reproducibly producing a pyrrolopyrimidine ring-containing tricyclic compound in high yield with reduced formation of by-products, and to provide a novel tricyclic compound capable of being obtained by this production method. The present invention provides a method for producing a compound represented by Formula (1) or a salt thereof, the method comprising the steps of: (I) causing an organic borane reagent to act on a compound represented by Formula (2) or a salt thereof, and (II) performing an intramolecular cyclization reaction of the reaction product of step (I) above using a zerovalent palladium catalyst in the presence of an alkali metal hydroxide.
    本发明的目的是提供一种方法,以高收率可重复地生产含有吡咯吡嘧啶环的三环化合物,并减少副产物的形成,并提供一种能够通过这种生产方法获得的新型三环化合物。本发明提供了一种制备由式(1)或其盐所表示的化合物的方法,该方法包括以下步骤:(I)使有机硼试剂作用于由式(2)或其盐所表示的化合物,和(II)在碱金属氢氧化物存在下,使用零价钯催化剂对步骤(I)中的反应产物进行分子内环化反应。
  • METHOD FOR PRODUCING TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:EP2960241A1
    公开(公告)日:2015-12-30
    An object of the present invention is to provide a method for reproducibly producing a pyrrolopyrimidine ring-containing tricyclic compound in high yield with reduced formation of by-products, and to provide a novel tricyclic compound capable of being obtained by this production method. The present invention provides a method for producing a compound represented by Formula (1) or a salt thereof, the method comprising the steps of: (I) causing an organic borane reagent to act on a compound represented by Formula (2) or a salt thereof, and (II) performing an intramolecular cyclization reaction of the reaction product of step (I) above using a zerovalent palladium catalyst in the presence of an alkali metal hydroxide.
    本发明的目的是提供一种高产率、减少副产物形成的可重复生产含吡咯并嘧啶环的三环化合物的方法,并提供一种可通过该生产方法获得的新型三环化合物。本发明提供了一种生产式(1)代表的化合物或其盐的方法,该方法包括以下步骤:(I)使有机硼烷试剂作用于式(2)所代表的化合物或其盐,和(II)在碱金属氢氧化物存在下,使用零价钯催化剂对上述步骤(I)的反应产物进行分子内环化反应。
  • QUINOLYLPYRROLOPYRIMIDYL FUSED-RING COMPOUND OR SALT THEREOF
    申请人:Taiho Pharmaceutical Co., Ltd.
    公开号:EP2722332B1
    公开(公告)日:2016-04-20
  • US8889666B2
    申请人:——
    公开号:US8889666B2
    公开(公告)日:2014-11-18
查看更多

同类化合物

环戊二烯并[4,5]氮杂卓并[2,1,7-cd]吡咯里嗪 吡咯并[1,2-a]氮杂-5-酮 六氢-1H-吡咯并[1,2-A]氮杂卓-5(6H)-酮 N,N-二甲基-3-(3-甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)丙-1-胺 9-氟-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 7,8-二氢-5H-吡咯并[1,2-A]氮杂环庚烷-9(6H)-酮 6-叔-丁基3A-乙基八氢吡咯并[2,3-D]氮杂卓-3A,6(2H)-二甲酸基酯 6,7-二氢吡咯并[2,3-c]氮杂卓-4,8(1H,5H)-二酮 5H-吡咯并[1,2-a]氮杂卓-7-醇 5,9:7,11-二亚甲基-5H-吡咯并[1,2-a]吖壬英-3-羧酸,6,7,8,9,10,11-六氢-,甲基酯 4-(2-氨基-1H-咪唑-5-基)-2,3-二溴-6,7-二氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1H-咪唑-4-基)-2,3-二溴-4,5,6,7-四氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1,5-二氢-5-氧代-4H-咪唑-4-亚基)-4,5,6,7-四氢-吡咯并[2,3-c]氮杂卓-8(1H)-酮 3-苄基-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 3-(3,9-二甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)-N,N-二甲基丙烷-1-胺 2H,3H-氧杂环丁烷并[3,2-d]吡咯并[1,2-a]氮杂卓 2-溴-6,7-二氢-1h,5h-吡咯并[2,3-c]氮杂烷-4,8-二酮 2,5-已炔二醇 2,3,4,5-四氢-N,N-二甲基-2-(3,4,5-三甲氧基苯甲酰基)-氮杂卓并(3,4-b)吲哚-10(1H)-丙胺 11-氧杂-3,10-二氮杂三环[7.2.1.03,7]十二碳-1,4,6,9-四烯 1,4,5,6,7,8-六氢吡咯并[3,2-b]氮杂卓 1,2,3,4,5,6-六氢氮杂环庚烷[4,3-B]吲哚盐酸盐 1,2,3,4,5,6-六氢-9-甲基氮杂卓并[4,5-b]吲哚 1,2,3,4,5,6-六氢-6-甲基氮杂革[4,5-b]吲哚盐酸盐 1,2,3,4,5,6-六氢-3-甲基氮杂卓并[4,5-b]吲哚 (1R*,2E,11S*)-2-(cyclohexylmethylene)-1-(phenylsilyl)methyloctahydropyrrolo[1,2-a]azepine (R)-2-(6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepin-9-yl)-acetaldehyde curvulamine (3aR,8aS)-tert-butyl octahydropyrrolo[3,4-d]azepine-2(1H)-carboxylate hydrochloride tert-butyl 6-(2-amino-2-oxoethyl)-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate 3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-(tert-butyloxycarbonyl)-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethylazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethyl-6-methylazepino[4,5-b]indole (Z)-2,3,9,9a-tetrahydro-6,6-dimethyl-9-methylene-8-vinyl-1H-pyrrolo[1,2-a]azepin-5(6H)-one 2,3,4,5,6,7-hexahydro-1H-3a,8,13,13b-tetraazabenzo[b]cyclopenta[1,2,3-jk]fluorene 2,3,4,5,6,7-hexahydro-1H-3a,8,11,11b-tetraazacyclohepta[1,2,3-jk]fluorene 1-Benzyloxy-2-methoxy-7,8,9,10-tetrahydro-6H-azepino<1,2-a>indole-11-carbaldehyde 3-benzoyl-10-(2-propoxyphenyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 2-phenyl-2,4,5,6-tetrahydro-1H-6-azabenzo[a]cyclohepta[cd]azulen-1-one 2-carbetoxy-3-(N,N-dimethyl)aminomethyleneamino-8-oxo-8H-4,5,6,7-tetrahydropyrrolo<2,3-c>azepine 3-benzoyl-10-[2-(trifluoromethyl)phenyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-benzoyl-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 6-[2-(4-fluorophenyl)ethyl]-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-4-oxo-1,4,5,6,7,8-hexahydro-pyrrolo[3,2-c]azepine-2-carbaldehyde 6-(2-phenylethyl)-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 11-(tert-butyldimethylsilyloxy)-1-trimethylsilyl-3a,4,11,12-tetrahydro-3H-cyclopenta[5,6]azepine[1,2-a]indole-2-one tert-butyl 8,9-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl 9,10-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl (1R,4S)-1-(benzylcarbamoyl)-3-oxo-2-((S)-1-phenylethyl)-1,2,3,4,5,10-hexahydroazepino[3,4-b]indol-4-ylcarbamate